60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) shares are down during Friday’s premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.

On Wednesday, the stock surged almost 48% as the company announced that all patients in its babesiosis trial were cured after tafenoquine treatment.

Babesiosis is a malaria-like parasitic infection. It is caused by Babesia parasites that infect red blood cells, primarily transmitted by Ixodes scapularis (blacklegged/deer) ticks.

100% Cure Rate For Tick Disease

The company’s expanded use trial evaluated the ARAKODA regimen of tafenoquine combined with atovaquone and other antimalarials/antibiotics in patients with risk factors for severe disease with relapsing babesiosis who have previously failed conventional antimicrobial regimens.

The company highlighted the cure rate for relapsing babesiosis in immunosuppressed patients approaches 100% when tafenoquine is added to a patient’s treatment regimen.

Tafenoquine is currently approved for malaria prophylaxis under the name ARAKODA, but it is not yet FDA-approved for treating babesiosis.

60 Degrees Partners With Runway Health on ARAKODA Access

In January, 60 Degrees Pharmaceuticals partnered with Runway Health to expand pre-departure access to ARAKODA by integrating a travel-focused telehealth platform that lets international travelers obtain physician-led online consultations before visiting malaria-endemic regions.

60 Degrees Pharmaceuticals Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $17.60. Recent analyst moves include:

• HC Wainwright & Co.: Buy (Raises Target to $24.00) (Jan. 27)
• Ascendiant Capital: Buy (Lowers Target to $11.20) (Nov. 28, 2025)

60 Degrees Pharmaceuticals Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for 60 Degrees Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Weak (Score: 2.35) — Stock is underperforming the broader market.

The Verdict: 60 Degrees Pharmaceuticals’ Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the weak momentum score indicates challenges, the recent trial results may provide a catalyst for future growth.

SXTP Stock Price Activity: Shares were down 7.90% at $2.68 during premarket trading on Friday, according to Benzinga Pro data.

Image via Shutterstock